Initial therapy with protease inhibitor-sparing regimens: Evaluation of nevirapine and delavirdine

Clinical Infectious Diseases

Volumn 30, Issue SUPPL. 2, 2000, Pages

  Conway, B ^a  

^a Deparment of Pharmacology   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; DELAVIRDINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; NEVIRAPINE; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 0034458329     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313850     Document Type: Conference Paper

References (20)

1. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 cells per cubic millimetre or less
3. Analysis of long-term virologic data from the VIRACEPT (nelfinavir, NFV) 511 protocol using 3 HIV-RNA assays
4. Randomised placebo-controlled trial of ritonavir in advanced HIV disease
5. Development of a cervical fat pad following treatment with HIV-1 protease inhibitors
6. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance
7. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, Netherlands, Canada and Australia Study
8. Long-term follow-up of patients treated with nevirapine (NVP)-based combination therapy within the INCAS trial
9. Interim analysis of plasma viral burden reductions and CD4 increases in HIV-1-infected patients with Rescriptor, Retrovir and Epivir
10. Combination therapy for HIV: Towards long-term control of disease progression
11. A phase II, multicenter, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) and indinavir (IDV) versus EFV and zidovudine (ZDV) and lamivudine (3TC), versus IDV, ZDV and 3TC at 24 weeks (DMP 266-006)
12. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immuno-deficiency virus infection
13. Randomised, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients
14. 10 reduction in clinical trials
15. An open-label, randomised, comparative study of d4T/3TC/IDV versus ZDV/3TC/IDV in treatment-naive HIV infected patients
16. An open-label, randomised, comparative study of d4T/ddI/IDV versus ZDV/3TC/IDV in treatment-naive HIV infected
17. Nevirapine resistance mutations of human immunodeficiency virus type I selected during therapy
18. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor